The minimum effective dose of propofol for upper gastrointestinal endoscopy sedation in patients with chronic alcoholism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040382

Enrollment

Unknown

Registered

2020-11-28

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic alcoholism

Interventions

Experimental group:chronic alcoholism

Control group:non drinker patients

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: We recruited 30 male chronic alcoholic and non-alcoholic patients aged 18-65 years with ASA grade I - II undergoing upper gastrointestinal endoscopy.

Exclusion criteria

Exclusion criteria: Patients with abnormal liver and kidney function, liver cirrhosis, contraindications of propofol, not received informed consent, BMI > 30, smoking index > 400

Design outcomes

Primary

Measure	Time frame
ED50;	—

Countries

China

Contacts

Public ContactHao Peipei

Capital Medical University

1309365819@qq.com+86 18618288955

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026